T cell fatigue, which lowers the durability and functioning of CAR-T cells and causes recurrence rates of up to 75% in patients undergoing CD19 or CD22 CAR-T therapies for hematological malignancies, poses a serious threat to the efficacy of CAR-T therapy. This evidence concerns the gene CD19 and hematologic disorder.